Vida Diagnostics, Inc., a Coralville, Iowa-based provider of AI-powered lung imaging analysis, raised $11M in initial close of its Series C financing.
The round was led by First Analysis Corporation with initial equity participation from Blue Heron Capital and UnityPoint Health Ventures and existing investors Next Level Ventures, Chartline Capital Partners, Rural Vitality Fund, Rittenhouse Ventures, Iowa First Capital Fund, and The Angels’ Forum.
The company will use the funds to accelerate the commercialization of its LungPrint® solution suite and by expanding LungPrint’s clinical portfolio.
Led by Susan A. Wood, Ph.D. and CEO, Vida provides pulmonary care by using AI-powered CT imaging software and services to aid the early detection, evaluation, and treatment planning of patients with or at risk of lung diseases, including emphysema and airway obstructive diseases (COPD), asthma, interstitial lung disease, and lung cancer. The software and services are FDA cleared, CE-marked, Health Canada licensed and TGA registered for clinical use in the US, European Economic Area, Canada and Australia.